287 related articles for article (PubMed ID: 2862139)
1. Molindone and haloperidol in tardive dyskinesia.
Glazer WM; Hafez HM; Benarroche CL
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):4-7. PubMed ID: 2862139
[TBL] [Abstract][Full Text] [Related]
2. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia.
Glazer WM; Hafez H
Schizophr Res; 1990; 3(5-6):315-20. PubMed ID: 1980827
[TBL] [Abstract][Full Text] [Related]
3. Review of clinical and laboratory experiences with molindone hydrochloride.
Claghorn JL
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):30-3. PubMed ID: 3894340
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the dopamine depressor response by molindone, a newly introduced neuroleptic.
Nandal NV; Mane VR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1980; 24(2):143-7. PubMed ID: 6103868
[TBL] [Abstract][Full Text] [Related]
5. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
6. Tardive dyskinesia: pathophysiology and animal models.
Casey DE
J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
[TBL] [Abstract][Full Text] [Related]
7. Long term treatment of tardive dyskinesia.
Jus A; Jus K; Fontaine P
J Clin Psychiatry; 1979 Feb; 40(2):72-7. PubMed ID: 33156
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
Casey DE
Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
10. The possible role of dopamine autoreceptors in neuroleptic atypicality.
Javitt DC; Weinstein SL; Opler LA
Psychiatr Dev; 1988; 6(1):57-71. PubMed ID: 2902622
[TBL] [Abstract][Full Text] [Related]
11. Molindone hydrochloride: a review of laboratory and clinical findings.
Owen RR; Cole JO
J Clin Psychopharmacol; 1989 Aug; 9(4):268-76. PubMed ID: 2671060
[TBL] [Abstract][Full Text] [Related]
12. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
13. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
14. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer WM
J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
[TBL] [Abstract][Full Text] [Related]
15. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
Dufresne RL; Wagner RL
J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
[TBL] [Abstract][Full Text] [Related]
17. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics.
Escobar JI; Mann JJ; Keller J; Wilkins J; Mason B; Mills MJ
J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):15-9. PubMed ID: 3894337
[TBL] [Abstract][Full Text] [Related]
18. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Koller W; Curtin J; Fields J
Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
[TBL] [Abstract][Full Text] [Related]
19. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
Ezrin-Waters C; Seeman MV; Seeman P
J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
[TBL] [Abstract][Full Text] [Related]
20. Atypical and typical neuroleptics and tardive dyskinesia.
Borison RL; Shah C; White TH; Diamond BI
Psychopharmacol Bull; 1987; 23(1):218-20. PubMed ID: 3602323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
